Shots:

• The first patient has been dosed in the P-IIb (VITALIZE) trial to evaluate the clinical benefit of IMV’s MVP-S + Merck’s Keytruda with/out CPA in ~150 patients with r/r DLBCL who have received 2 prior lines of systemic therapy & ineligible or failed ASCT or CAR-T therapy. The results are expected in summer 2022
• The 1EPs is ORR and measured by the number of patients achieving the best response of PR & CR @2yr. treatment period while exploratory EPs include cell-mediated immune response, tumor immune cell infiltration, and biomarker analysis
• Additionally, the results from the (SPiReL) study showed that MVP-S + Keytruda induced DCR, grade 1 or 2 AEs & showed 75% ORR in PD-L1+ patients

Ref: IMV | Image: IMV